Nyxoah (NYXH) has released an update.
Nyxoah, a medical technology firm, has secured a €37.5 million loan from the European Investment Bank to bolster its research and development, and expand manufacturing for its OSA treatment solutions in Europe and the U.S. The loan, supported by the InvestEU program, will be distributed in three tranches, with each accompanied by synthetic warrants providing the EIB with potential future cash returns. CEO Olivier Taelman expresses gratitude for the support, which complements recent equity offerings and propels the commercialization and production of their Genio system.
For further insights into NYXH stock, check out TipRanks’ Stock Analysis page.
